Developer docs
API playgroundTry for free, no card

Search company profiles

Corlieve Therapeutics

Full company profile

uuid000crx2

Namestring
Corlieve Therapeutics
Websiteurl
corlieve.com
Company typeenum
Private
Founded yearint
2019
Short descriptiontext

Corlieve Therapeutics is a Paris-based clinical-stage biotechnology company founded in 2019, operating in the cell and gene therapy sector as a fully owned subsidiary of uniQure N.V. The company focuses on advanced therapy development with 11-50 employees.

Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
gene therapy, cell therapy, biopharmaceuticals, neurological therapeutics, CNS gene therapy
Industry3 codes
1Neurology/CNS Gene Therapies
CodeHLAAACAHPrimaryYes
2Gene Therapy for Rare/Monogenic Diseases
CodeHLAAACAEPrimaryNo
3Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
CodeHLAAACANPrimaryNo
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceuticals / Gene Therapy
Social media profiles1 record
Cost components4 values
Technology or R&D, Personnel, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Corlieve Therapeutics develops gene therapy candidates targeting neurological disorders, with operational focus on chemistry, manufacturing, and controls (CMC) for clinical-stage gene therapy programs. The company operates as a wholly owned subsidiary of uniQure N.V., contributing specialized CNS-directed gene therapy assets to its parent company's portfolio.

Differentiator
Functional benefit
Problem solved
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Peers10 records
1Lysogene
TypeDirect peer
Description

Paris-based clinical-stage gene therapy company developing AAV-based treatments for severe CNS diseases including Sanfilippo syndrome type A. Comparable to Corlieve on Paris-based European biotech positioning, CNS focus, and AAV platform.

2Prevail Therapeutics (Eli Lilly)
TypeDirect peer
Description

Acquired by Eli Lilly in 2021, Prevail develops AAV-based gene therapies for Parkinson's disease and other neurodegenerative disorders. Comparable to Corlieve in CNS-targeted AAV gene therapy focus and serves as a precedent for strategic acquisition of similar platforms.

3Adverum Biotechnologies
TypeDirect peer
Description

Clinical-stage gene therapy company developing AAV-based treatments for ocular and CNS diseases including wet AMD and genetic CNS conditions. Comparable to Corlieve in AAV gene therapy modality and neurology-adjacent indications.

4Passage Bio
TypeDirect peer
Description

Clinical-stage genetic medicines company developing AAV-delivered therapeutics for rare monogenic CNS diseases including GM1 gangliosidosis, Krabbe disease, and frontotemporal dementia. Highly comparable to Corlieve on indication strategy (rare CNS monogenic) and AAV delivery platform.

5uniQure N.V.
TypeBroad incumbent
Description

Parent company of Corlieve and a leading clinical-stage gene therapy company with AAV platforms targeting CNS indications (Huntington's, refractory epilepsy) and other diseases. Directly comparable because Corlieve's pipeline and operations are fully integrated within uniQure's CNS gene therapy franchise.

6Asklepios BioPharmaceutical (AskBio, Bayer)
TypeBroad incumbent
Description

Clinical-stage gene therapy company (acquired by Bayer in 2020) developing AAV-based treatments across multiple therapeutic areas including CNS (e.g., Friedreich's ataxia, Huntington's, Pompe disease). Comparable to Corlieve as a broad AAV gene therapy platform with CNS programs.

7Voyager Therapeutics
TypeDirect peer
Description

Clinical-stage gene therapy company developing AAV-based treatments for severe neurological diseases including Parkinson's disease, Huntington's disease, and ALS. Directly comparable to Corlieve in CNS AAV gene therapy focus, modality, and target indications.

8REGENXBIO
TypeBroad incumbent
Description

Clinical-stage biotechnology company developing AAV gene therapies, including CNS-targeted programs (RGX-121 for MPS II) and proprietary NAV technology platform. Comparable to Corlieve as a broader AAV gene therapy player with overlapping CNS rare-disease programs.

9Taysha Gene Therapies
TypeDirect peer
Description

Clinical-stage gene therapy company focused on AAV-based treatments for monogenic CNS diseases, with a pipeline including Rett syndrome and CLN1 disease. Comparable to Corlieve in CNS monogenic disease focus and AAV modality.

10GenSight Biologics
TypeDirect peer
Description

Paris-based clinical-stage gene therapy company developing AAV-based treatments for neurodegenerative diseases of the eye and CNS, including Leber hereditary optic neuropathy (LHON). Comparable to Corlieve as a Paris-headquartered European CNS/neurology gene therapy specialist using AAV vectors.

Market position
Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Corlieve Therapeutics

Biopharmaceuticals / Gene Therapycorlieve.com

Corlieve Therapeutics is a Paris-based clinical-stage biotechnology company founded in 2019, operating in the cell and gene therapy sector as a fully owned subsidiary of uniQure N.V. The company focuses on advanced therapy development with 11-50 employees.

Corlieve Therapeutics firmographics

Firmographics
Name
Corlieve Therapeutics
Website
https://corlieve.com
Company type
Private
Founded year
2019
Headcount range
11–50 employees
Short description
Corlieve Therapeutics is a Paris-based clinical-stage biotechnology company founded in 2019, operating in the cell and gene therapy sector as a fully owned subsidiary of uniQure N.V. The company focuses on advanced therapy development with 11-50 employees.
Ownership category
akta.pro rank

Corlieve Therapeutics industry classification

Industry
Product category
Biopharmaceuticals / Gene Therapy
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro primary industry
Neurology/CNS Gene Therapies (HLAAACAH)
akta.pro secondary industries
Gene Therapy for Rare/Monogenic Diseases (HLAAACAE), Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN)

Keywords

  • Gene therapy
  • Cell therapy
  • Biopharmaceuticals
  • Neurological therapeutics
  • CNS gene therapy

Where Corlieve Therapeutics is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Markets served

Corlieve Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain

Corlieve Therapeutics product offering

Product offering

Core offering

Corlieve Therapeutics develops gene therapy candidates targeting neurological disorders, with operational focus on chemistry, manufacturing, and controls (CMC) for clinical-stage gene therapy programs. The company operates as a wholly owned subsidiary of uniQure N.V., contributing specialized CNS-directed gene therapy assets to its parent company's portfolio.

Differentiator

Problem solved

Functional benefit

Companies that use Corlieve Therapeutics

Customer profile

Ideal customer profiles1 record

Corlieve Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Corlieve Therapeutics partnerships and signals

Strategic signal

Scale indicators3 records

Corlieve Therapeutics competitors and assessment

Company assessment

Direct peers

  • Lysogene: Paris-based clinical-stage gene therapy company developing AAV-based treatments for severe CNS diseases including Sanfilippo syndrome type A. Comparable to Corlieve on Paris-based European biotech positioning, CNS focus, and AAV platform.
  • Prevail Therapeutics (Eli Lilly): Acquired by Eli Lilly in 2021, Prevail develops AAV-based gene therapies for Parkinson's disease and other neurodegenerative disorders. Comparable to Corlieve in CNS-targeted AAV gene therapy focus and serves as a precedent for strategic acquisition of similar platforms.
  • Adverum Biotechnologies: Clinical-stage gene therapy company developing AAV-based treatments for ocular and CNS diseases including wet AMD and genetic CNS conditions. Comparable to Corlieve in AAV gene therapy modality and neurology-adjacent indications.
  • Passage Bio: Clinical-stage genetic medicines company developing AAV-delivered therapeutics for rare monogenic CNS diseases including GM1 gangliosidosis, Krabbe disease, and frontotemporal dementia. Highly comparable to Corlieve on indication strategy (rare CNS monogenic) and AAV delivery platform.
  • Voyager Therapeutics: Clinical-stage gene therapy company developing AAV-based treatments for severe neurological diseases including Parkinson's disease, Huntington's disease, and ALS. Directly comparable to Corlieve in CNS AAV gene therapy focus, modality, and target indications.
  • Taysha Gene Therapies: Clinical-stage gene therapy company focused on AAV-based treatments for monogenic CNS diseases, with a pipeline including Rett syndrome and CLN1 disease. Comparable to Corlieve in CNS monogenic disease focus and AAV modality.
  • GenSight Biologics: Paris-based clinical-stage gene therapy company developing AAV-based treatments for neurodegenerative diseases of the eye and CNS, including Leber hereditary optic neuropathy (LHON). Comparable to Corlieve as a Paris-headquartered European CNS/neurology gene therapy specialist using AAV vectors.

Broad incumbents

  • uniQure N.V. Parent company of Corlieve and a leading clinical-stage gene therapy company with AAV platforms targeting CNS indications (Huntington's, refractory epilepsy) and other diseases. Directly comparable because Corlieve's pipeline and operations are fully integrated within uniQure's CNS gene therapy franchise.
  • Asklepios BioPharmaceutical (AskBio, Bayer): Clinical-stage gene therapy company (acquired by Bayer in 2020) developing AAV-based treatments across multiple therapeutic areas including CNS (e.g., Friedreich's ataxia, Huntington's, Pompe disease). Comparable to Corlieve as a broad AAV gene therapy platform with CNS programs.
  • REGENXBIO: Clinical-stage biotechnology company developing AAV gene therapies, including CNS-targeted programs (RGX-121 for MPS II) and proprietary NAV technology platform. Comparable to Corlieve as a broader AAV gene therapy player with overlapping CNS rare-disease programs.

Market position

Customer concentration

Corlieve Therapeutics social profiles

Digital presence

Corlieve Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Corlieve Therapeutics leadership team

Management profile

Number of profiles

Profiles1 record

Corlieve Therapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Corlieve Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Corlieve Therapeutics

What does Corlieve Therapeutics do?

Corlieve Therapeutics develops gene therapy candidates targeting neurological disorders, with operational focus on chemistry, manufacturing, and controls (CMC) for clinical-stage gene therapy programs. The company operates as a wholly owned subsidiary of uniQure N.V., contributing specialized CNS-directed gene therapy assets to its parent company's portfolio.

When was Corlieve Therapeutics founded?

Corlieve Therapeutics was founded in 2019. It employs 11 to 50 people.

Where is Corlieve Therapeutics based?

Corlieve Therapeutics is headquartered in Paris, France, in the Europe region.

Who are Corlieve Therapeutics's main competitors?

Direct peers on record are Lysogene, Prevail Therapeutics (Eli Lilly), Adverum Biotechnologies, Passage Bio, Voyager Therapeutics, Taysha Gene Therapies and GenSight Biologics. Broad incumbents are uniQure N.V., Asklepios BioPharmaceutical (AskBio, Bayer) and REGENXBIO.

Does Corlieve Therapeutics have an API?

No public API is recorded for Corlieve Therapeutics.

What industry is Corlieve Therapeutics in?

Corlieve Therapeutics's product category is Biopharmaceuticals / Gene Therapy. Its primary akta.pro industry code is HLAAACAH, Neurology/CNS Gene Therapies, with a secondary code of HLAAACAE, Gene Therapy for Rare/Monogenic Diseases. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
European BiotechnologyKurma Partners closes Biofund IV at €215M, giving European biotech a fresh specialist pool of capitalKurma Partners closed Biofund IV at €215 million, below its €250 million target, giving European biotech founders a new capital source. The fund will back 16-20 companies, with 80% focused on new therapeutic solutions. Early investments include Memo Therapeutics, Avidicure, and EvlaBio.MarketScreenerUniQure N.V. completed the acquisition of Corlieve Therapeutics SAS.UniQure N.V. completed the acquisition of Corlieve Therapeutics SAS, expanding its gene therapy portfolio. This transaction represents a strategic move by UniQure to enhance its capabilities in developing one-time administered treatments for genetic diseases.GlobeNewswireuniQure to Acquire Corlieve Therapeutics and AdvanceuniQure agreed to acquire Corlieve Therapeutics and its lead gene therapy AMT-260 for temporal lobe epilepsy, paying €46.3 million upfront. The deal includes up to €160 million in development milestones and is expected to close in Q3 2021.FinSMEsCorlieve Therapeutics Completes Seed FinancingCorlieve Therapeutics closed an undisclosed seed financing round led by Kurma Partners and IDinvest Partners. The funds will support development of its AAV gene therapy for refractory temporal lobe epilepsy, a program developed with REGENXBIO.PR NewswireCorlieve Therapeutics SAS schließt die Seed-Finanzierung zur Entwicklung von Therapien für schwere neurologische ErkrankungenCorlieve Therapeutics announced the closing of its seed funding round, led by Kurma Partners and IDinvest Partners together with Pureos Bioventures, to support development of new therapeutics for severe neurological diseases. The company's lead program employs a novel AAV gene therapy approach targeting refractory temporal lobe epilepsy (TLE) and is based on research from French institutions (INSERM, CNRS, Aix Marseille University, University of Bordeaux), developed in collaboration with REGENXBIO Inc. using the licensed NAV AAV9 technology. CEO Richard Porter, formerly COO of Therachon Holding AG (acquired by Pfizer in 2019), will lead the company.PR NewswireCorlieve Therapeutics SAS Closes Seed Financing to Develop Therapies for Severe Neurological ConditionsCorlieve Therapeutics SAS announced the closing of its seed financing round led by Kurma Partners and IDinvest Partners, together with Pureos Bioventures, to advance novel AAV gene therapy treatments for severe neurological disorders. The company's lead program targets refractory temporal lobe epilepsy using technology licensed from REGENXBIO Inc., based on science developed through collaborations with French research institutions INSERM, CNRS, Aix Marseille University, and the University of Bordeaux. The financing will support the development of this gene therapy approach while REGENXBIO provides its NAV AAV9 technology platform and serves on Corlieve's board.PR NewswireCorlieve Therapeutics SAS cierra una financiación semilla para desarrollar terapiasCorlieve Therapeutics SAS announced the closing of a seed funding round led by Kurma Partners and IDinvest Partners, with participation from Pureos Bioventures, to advance therapies for severe neurological conditions. The company's lead program uses a novel AAV gene therapy approach for treating refractory temporal lobe epilepsy (TLE), based on science from French research institutions and developed in collaboration with REGENXBIO Inc. Corlieve has licensed REGENXBIO's NAV AAV9 technology for the TLE program.